Science and Research
The Microcyn®Technology is unique in many ways.

 

It is....

Developed and produced by Sonoma Pharmaceuticals (Nasdaq: SNOA), formerly Oculus Innovative Sciences Inc. (Nasdaq:OCLS), a U.S. listed  biopharmaceutical company(GMP) under continuous refinement for over 16 years

The original and very first hypochlorous acid (HOCl) introduced into the U.S. advanced wound care market

World’s best selling hypochlorous (HOCl) wound treatment product healing over 5 million people, without any significant adverse events.

Used daily in over 20 countries and over 400 hospitals in the U.S.

Its unique solution chemistry is proven safe and effective in helping to reduce itch, scarring, inflammation, skin infection and improved healing in over 40+ clinical trials

Patented by 53 issued patents and 109 pending patents worldwide

Has obtained 16 FDA (U.S. Food and Drug Administration) and 20 CE (Conformité Européenne) approvals

Registered under MDCO (Medical Device Control Office) in the Department of Health of Hong Kong for Microdacyn60

Our story

Find out about why we do it

Forumulation characteristics and significance
Check out what's in our product and why it's important

登入/成為會員

0

Contact Us 聯絡我們:

Microderm Technologies Ltd

E: info@dermodacyn.com

M - F: 9am - 6pm

Enquiries

歡迎電話查詢

T: +852 3727 2988

  • YouTube Social  Icon
  • Facebook Basic Black

© 2019 by Microderm Technologies Limited.                                                                                                                                                                                                                 Our Policy 條款及細則